Anagrelide hydrochloride , 98% , 58579-51-4

Synonym(s):
6,7-Dichloro-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one hydrochloride

CAS NO.：58579-51-4

Empirical Formula: C10H8Cl3N3O

Molecular Weight: 292.55

MDL number: MFCD01720337

EINECS: 680-360-9

PRODUCT Properties

• Melting point: >280°C
• storage temp.: 2-8°C
• solubility: DMSO: soluble1mg/mL, clear (warmed)
• form: powder
• color: white to beige
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Description and Uses

Anagrelide hydrochloride was launched in the US for thrombocytosis (essential or associated with chronic myelogenous leukemia). The imidazoquinazoline derivative can be prepared from 2,5,6-trichloro-3,4-dihydropyrimidine via alkylation with ethyl bromoacetate followed by heating with ethanolic ammonia or treatment of N-(a-amino- 5,6-dichlorobenzyl)glycine ethyl ester with cyanogen bromide. As a result of its anti-cAMP phosphodiesterase (PDE Ⅲ) activity, Anagrelide hydrochloride was initially tested as a platelet aggregation inhibitor. However it was found that at much lower concentrations it became thrombocytopenic. While the mechanism is not fully understood, it did not shorten platelet survival nor inhibit the formation of colony-forming unitsmegakaryocytes (CFU-M) but primarily interfered with the maturation of megakaryocytes (reduction in size with altered ploidy). It did decrease peripheral vascular resistance and had a positive inotropic effect.

Anagrelide Hydrochloride is a phosphodiesterase inhibitor with antiplatelet activity. Used as an antithrombocythemic. Potent PDE3 inhibitor.

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H351-H361d-H413
• Precautionary statements: P202-P273-P280-P308+P313-P405-P501
• Hazard Codes: Xn
• Risk Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3